-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Leading cardio-cerebrovascular and peripheral vascular minimally invasive interventional medical device company-LifeTech announced that the FIM study of the company's innovative product G-Branch™ thoracic-abdominal aorta stent graft system has completed the enrollment of all patients, and the mid-term The follow-up results were excellent
.
The G-Branch™ thoracic-abdominal aorta stent graft system was developed by LifeTech and Professor Guo Wei from the Department of Cardiovascular Surgery of the First Medicine of the Chinese People's Liberation Army General Hospital and his team.
It is suitable for the intracavitary reconstruction of thoracic-abdominal aortic aneurysms
.
This product is innovatively developed to solve the international problem of multi-branch arterial intraluminal reconstruction.
The FIM study of the G-Branch™ thoracic-abdominal aorta stent graft system was led by Professor Guo Wei as the principal investigator (PI).
All subjects were enrolled in March this year, and all patients are currently in the follow-up phase
.
The follow-up results for six months and one year after the operation showed that the subjects were in good condition, and there was no endoleak, stent displacement, and branch vessel stenosis or occlusion, which preliminarily proved the G-Branch™ thoracic-abdominal aortic graft The safety and effectiveness of the stent system in the treatment of thoracic-abdominal aortic aneurysms
Thoracic-abdominal aortic aneurysm is a disease with extremely high mortality, and its incidence accounts for about 7%-15% of all aortic aneurysm-like dilated lesions.
If not treated in time, the 2-year and 5-year mortality rates are about 76% and 76% respectively.
95%[1]
.
Due to the wide range of involvement of thoracic-abdominal aortic aneurysms, it involves the intracavitary reconstruction of important visceral branches in the thoracic cavity, abdominal cavity, and thoracic-abdominal joints, which is a major challenge faced by intracavitary techniques such as EVAR/TEVAR, and there is currently no effective intervention.
LifeTech’s G-Branch™ Thoracic-Abdominal Aorta Stent Graft System provides an excellent innovative device solution to solve this problem.
It can realize branch vessel reconstruction under complete endoluminal technology and maintain continuous blood in various organs during surgery.
For
.
The main stent of this product is pre-installed with two embedded branch stents, and a pair of short branch stents are pre-connected on both sides of the main stent.
The FIM study of G-Branch™ Thoracic and Abdominal Aorta Stent Graft System was completed and the mid-term follow-up results were excellent, marking a very critical step in the commercialization of this innovative product
.
Professor Guo Wei, the principal investigator (PI) of G-Branch™, said: “At present, there are still great challenges in the intraluminal reconstruction of visceral arteries.
